The Divisional Game: Using Procedural Rights to Impede Generic/Biosimilar Market Entry
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2195-0237
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
The Divisional Game: Using Procedural Rights to Impede Generic/Biosimilar Market Entry ; volume:53 ; number:7 ; day:4 ; month:8 ; year:2022 ; pages:1007-1037 ; date:8.2022
International review of intellectual property and competition law ; 53, Heft 7 (4.8.2022), 1007-1037, 8.2022
- Classification
-
Recht
- Creator
-
Foss-Solbrekk, Katarina
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40319-022-01225-3
- URN
-
urn:nbn:de:101:1-2022112709113985646636
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
11.06.2025, 2:23 PM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Foss-Solbrekk, Katarina
- SpringerLink (Online service)
Other Objects (12)
Authorized Generic Entry prior to Patent Expiry: Reassessing Incentives for Independent Generic Entry
Authorized Generic Entry prior to Patent Expiry: Reassessing Incentives for Independent Generic Entry
Implementing EU consumer rights by national procedural law
Procedural rights in competition law in the EU and China
Analogical lightweight ontology of EU criminal procedural rights in judicial cooperation
Estimations of generic drug entry in Brazil using count versus ordered models
Estimations of generic drug entry in Brazil using count versus ordered models
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
AVT04: An Ustekinumab Biosimilar
AVT02: An Adalimumab Biosimilar
SB8: A Bevacizumab Biosimilar
Procedural dermatology
Authorized Generic Entry prior to Patent Expiry: Reassessing Incentives for Independent Generic Entry
Authorized Generic Entry prior to Patent Expiry: Reassessing Incentives for Independent Generic Entry
Implementing EU consumer rights by national procedural law
Procedural rights in competition law in the EU and China
Analogical lightweight ontology of EU criminal procedural rights in judicial cooperation
Estimations of generic drug entry in Brazil using count versus ordered models
Estimations of generic drug entry in Brazil using count versus ordered models
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
AVT04: An Ustekinumab Biosimilar
AVT02: An Adalimumab Biosimilar
SB8: A Bevacizumab Biosimilar
Procedural dermatology
Authorized Generic Entry prior to Patent Expiry: Reassessing Incentives for Independent Generic Entry
Authorized Generic Entry prior to Patent Expiry: Reassessing Incentives for Independent Generic Entry
Implementing EU consumer rights by national procedural law
Procedural rights in competition law in the EU and China
Analogical lightweight ontology of EU criminal procedural rights in judicial cooperation
Estimations of generic drug entry in Brazil using count versus ordered models
Estimations of generic drug entry in Brazil using count versus ordered models
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
AVT04: An Ustekinumab Biosimilar
AVT02: An Adalimumab Biosimilar
SB8: A Bevacizumab Biosimilar